Lilly's orforglipron hits weight-loss goal in Japanese Phase 3 trial
The ATTAIN-J study of Lilly's oral GLP-1 pill met its body-weight endpoints in Japanese adults with obesity, adding a third positive Phase 3 readout to the drug's global dataset.
Executive Summary
- Eli Lilly's oral GLP-1 receptor agonist orforglipron met its primary body-weight endpoints in a Phase 3 trial run entirely in Japanese adults with obesity, adding a third positive Phase 3 readout to the drug's global dataset.
- The result functions as a bridging study supporting the dose and population Lilly is relying on for its Japan regulatory submission, rather than a new efficacy test for the molecule.
- Orforglipron enters a field with more than a dozen direct oral and injectable GLP-1 receptor programs in obesity already in Phase 3, so this readout's value is confirming consistency with the drug's own prior results rather than differentiating it from rivals.
- The trial enrolled to its target, completed on schedule relative to its own registry history, and shows no material timing or protocol instability bearing on the reliability of this readout.
What was tested
The trial, known as ATTAIN-J, enrolled 238 Japanese adults with obesity or overweight plus at least one weight-related condition such as hypertension, dyslipidemia, or type 2 diabetes. Participants were randomized to placebo or one of three doses of once-daily oral orforglipron, 6 mg, 12 mg, or 36 mg, for 72 weeks. The two primary endpoints were percent change in body weight from baseline at week 72 and the proportion of participants achieving at least 5% body weight reduction, both measured against placebo. Twenty secondary endpoints covered waist circumference, blood pressure, lipids, glycemic measures, and quality-of-life scores. NCT05931380A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity DiseaseNCT05931380
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
How it fits the program
This is the third Phase 3 readout for orforglipron to post results. In the global ATTAIN-2 trial, the 36 mg dose lowered body weight by 10.5% versus 2.2% for placebo at 72 weeks in a population with obesity or overweight and type 2 diabetes, with all three doses meeting primary and key secondary endpoints. In the ATTAIN-MAINTAIN trial, orforglipron met its primary endpoint of superior weight-loss maintenance at 52 weeks against placebo, with prespecified subgroup differences of 0.9 kg for patients switching from Wegovy and 5.0 kg for those switching from Zepbound. ATTAIN-J adds a third data point testing the same molecule in a Japanese population, where regulatory and dosing questions can differ from the global program.
Regulatory context
Lilly has already told investors it submitted orforglipron for obesity to Japanese regulatory authorities, a submission the company described as completed without specifying exact timing. Orforglipron holds an FDA-cleared brand name, Foundayo, tied to an approved New Drug Application in the United States. The Japanese filing sits alongside that US regulatory track, and ATTAIN-J is the trial most directly built to support the Japan-specific dossier. AA Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity DiseaseJul 20, 2026
The competitive field
Orforglipron competes in a field of at least 17 direct-tier GLP-1 receptor programs in obesity, spanning oral small molecules from AstraZeneca (elecoglipron), Roche (enicepatide), and Structure Therapeutics' Gasherbrum Bio unit (aleniglipron), alongside injectable peptides from Novo Nordisk (semaglutide, CagriSema) and Amgen (maridebart cafraglutide). Within that group, orforglipron and elecoglipron are among the small-molecule oral entrants competing against the injectable incumbents on route rather than target, a distinction that matters because an oral pill removes the injection-device burden that has shaped adherence in this class. Against that landscape, an isolated Japan bridging trial does not move the field; what it establishes is that the drug's weight-loss effect held in a population outside the trials that already anchor the Japan submission.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.